Evolent Health Enters Agreement with Bright HealthCare for Bright HealthCare to Acquire True Health New Mexico
News provided by
Share this article
Share this article
WASHINGTON, Jan. 13, 2021 /PRNewswire/ Evolent Health, Inc. (NYSE: EVH) (the Company or Evolent ), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that it has entered a definitive agreement with Bright Health Management, Inc. ( Bright HealthCare ), a nationally recognized health plan owned by Bright Health, to acquire True Health New Mexico, Inc. ( TRUE ), a wholly-owned subsidiary of Evolent Health. The existing services contract between True Health New Mexico and Evolent will be maintained and as such, Evolent will continue to provide health plan administrative and clinical program support to True Health New Mexico.
Share this article
Share this article
HOUSTON, Jan. 13, 2021 /PRNewswire/ Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it has completed the construction and qualification of its cGMP manufacturing facility in Houston, TX, located near the George Bush Intercontinental Airport. The facility will allow production of MultiTAA-specific T cell products according to U.S. Food and Drug Administration (FDA) guidelines and is designed to be scalable using modular processes. The Company has initiated the technology transfer process and expects the cGMP manufacturing facility to be fully operational in the first half of 2021.
Porter s Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America pharmaceutical CDMO market in every aspect of the classification from perspectives of Category, Service Type, Therapeutic Application, End User, and Country.
Based on Category, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Pharmaceutical Industry
Biopharmaceutical Industry
Based on Service Type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
United Therapeutics Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso® in Pulmonary Hypertension Associated with Interstitial Lung Disease
INCREASE Study is First to Demonstrate a Clear Benefit in Patients with PH-ILD, a Life-threatening Disease with No Currently FDA-Approved Treatments
Company to host a webcast detailing the INCREASE study results on Tuesday, January 19, 2021 at 4:30 p.m. E.T.
News provided by
Share this article
Share this article
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 13, 2021 /PRNewswire/ United Therapeutics Corporation (Nasdaq: UTHR) today announced that results from the
INCREASE clinical study of Tyvaso
® (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) have been published online in the
Share this article
Share this article
ResearchAndMarkets.com s offering.
This report describes the global market size of Sleep and Respiratory Care from 2015 to 2019 and its CAGR from 2015 to 2019, and also forecasts its market size to the end of 2025 and its CAGR from 2020 to 2025.
For the geography segment, regional supply, demand, major players, price is presented from 2015 to 2025.
This report covers the following regions:
North America